Clinical trials · New York, NY
Acute Leukemia clinical trials in New York
We’re tracking 107 recruiting acute leukemia studies with a site in or near New York — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT06852222RecruitingPhase 3
Study of bleximenib, venetoclax, and azacitidine for newly diagnosed AML
This trial tests a new drug combination (bleximenib, venetoclax, and azacitidine) for people with a specific genetic type of AML who cannot receive strong chemotherapy. The goal is to see if this combination is safer and more effective.
New York, New YorkAges 18 years+ - NCT06001788RecruitingPhase 1
Ziftomenib for relapsed or refractory acute myeloid leukemia
This trial tests a new drug combination called ziftomenib for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. Researchers will check how safe it is and what side effects happen.
New York, New YorkAges 18 years+ - NCT07107126RecruitingPhase 1
Testing a new drug for relapsed AML or high-risk MDS
This trial tests a new drug called RPT1G for adults with acute myeloid leukemia or high-risk myelodysplastic syndromes that have not responded to standard treatments. The goal is to see if the drug is safe and if it shows signs of helping control the disease.
New York, New YorkAges 18 years+ - NCT06017258RecruitingPhase 1
CAR T cell therapy for acute myeloid leukemia
This trial tests a new type of immune cell therapy (CAR T cells) for people with acute myeloid leukemia (AML) that has come back or not gone away after treatment. The therapy is designed to find and attack leukemia cells that have a specific marker called CD371.
New York, New YorkAges 1 year+ - NCT05375617Recruiting
Study for newly diagnosed childhood cancers in Europe
This study follows children and teens with newly diagnosed certain leukemia (ALL) and certain favorable brain tumors to learn best care and outcomes. It may help your team compare standard treatments and monitor health over time.
New York, New YorkAges 3–21 - NCT03802695RecruitingPhase 1
Orca-Q pill to help during stem cell transplant
This Phase 1 trial studies Orca-Q to see if it is safe and works when added around the time of an allogeneic (donor) stem cell transplant for certain blood cancers. If you qualify, the study may offer a new option for managing the transplant immune response.
New York, New YorkAges 12–78 - NCT06824168RecruitingPhase 2
Quizartinib maintenance for FLT3-ITD AML in remission
This trial tests two different doses of an oral targeted pill called quizartinib (a FLT3 inhibitor) to keep AML with a FLT3-ITD mutation in remission after initial chemo. If you are in first complete remission and haven't had a transplant, this might be an option to lower the chance of relapse.
New York, New YorkAges 18 years+ - NCT07392242RecruitingPhase 2
Ivosidenib, azacitidine, and venetoclax for acute myeloid leukemia
This trial tests a combination of three targeted drugs for people with a specific type of AML that has an IDH1 mutation. The goal is to see if the combination helps control the leukemia and if continuing with just ivosidenib can keep it in remission.
New York, New YorkAges 60 years+ - NCT02143830RecruitingPhase 2
Stem cell transplant chemotherapy for Fanconi anemia
This Phase 2 study tests a stem cell transplant approach using adjusted chemotherapy doses for people with Fanconi anemia. It may help replace damaged bone marrow and treat blood problems like severe aplastic anemia, MDS, or leukemia.
New York, New YorkAges 3 months+ - NCT02074839RecruitingPhase 1
Oral AG-120 for advanced blood cancers with an IDH1 mutation
This Phase 1 study tests an oral medicine called AG-120 in adults with advanced blood cancers that have a specific IDH1 mutation. It also looks at safety and how the treatment works, with frequent blood, urine, and bone marrow samples.
New York, New YorkAges 18 years+ - NCT07320235RecruitingPhase 1
Combination treatment for relapsed AML
This trial tests a new combination of drugs for people whose acute myeloid leukemia (AML) has come back or not responded after at least one prior treatment, and who have no other standard options. The goal is to see if adding imetelstat to other therapies can help.
New York, New YorkAges 18 years+ - NCT03959085RecruitingPhase 3
Inotuzumab plus chemotherapy for high-risk childhood leukemia
This Phase 3 trial tests whether adding inotuzumab to standard post-induction chemotherapy improves outcomes for children and young teens with high-risk B-ALL, mixed phenotype acute leukemia (MPAL), or certain high-risk B-LLy. It may help by targeting leukemia cells more directly, but participation depends on specific age, lab results, and medical history rules.
New York, New YorkAges 12 months–25 years - NCT06247787RecruitingPhase 1
Imetelstat plus chemo for relapsed leukemia in kids
This trial tests a new drug called imetelstat combined with two chemotherapy drugs (fludarabine and cytarabine) for children and teens with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) that has come back or not responded to treatment. The goal is to find the safest dose of imetelstat and see if it helps control the cancer.
New York, New YorkAges 1–18 - NCT02677064Recruiting
Study on barriers to stem cell transplant for acute leukemia
This study looks at what makes it hard for people with acute leukemia or related blood cancers to get a stem cell transplant. It aims to find ways to help more people get this treatment.
New York, New YorkAges 18–80 - NCT06137118RecruitingPhase 1/Phase 2
Study of AZD0486 for relapsed or refractory B-cell ALL
This trial tests a new investigational drug (AZD0486) given alone to see if it is safe and effective for people with B-cell acute lymphoblastic leukemia (ALL) that has come back or hasn't responded to treatment. It specifically targets a protein called CD19 found on leukemia cells.
New York, New YorkAges 12 years+ - NCT06773208RecruitingPhase 2
Azacitidine and venetoclax for people with AML in remission
This trial tests a combination of two drugs, azacitidine and venetoclax, for people with acute myeloid leukemia (AML) who have achieved remission after initial chemotherapy but still have tiny amounts of leukemia cells left (measurable residual disease). The goal is to see if this treatment can clear those remaining cells before a stem cell transplant.
New York, New YorkAges 18 years+ - NCT07070219RecruitingPhase 1/Phase 2
Study of CTD402 for T-cell leukemia or lymphoma
This trial tests a new drug called CTD402 for people with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) that has come back or not gone away after treatment. The goal is to see if CTD402 can help reduce or eliminate the cancer cells in the bone marrow.
New York, New YorkAges 1 year+ - NCT07586618RecruitingPhase 1
New Drug 4A10 for Hard-to-Treat Lymphoblastic Leukemia or Lymphoma
This is an early-stage study testing a new experimental drug (4A10) in patients whose acute lymphoblastic leukemia or lymphoblastic lymphoma has returned or stopped responding to standard treatments. Researchers want to learn if the drug is safe and how it works in the body.
New York, New YorkAges 18 years+ - NCT05929976Recruiting
Study of gut and blood chemistry in children with new leukemia
This study looks at the gut microbiome (tiny organisms in the gut) and metabolome (small chemicals in the body) in children and teens with newly diagnosed ALL. It may help researchers understand what is happening in the body early in treatment and could guide future, more personalized care.
New York, New YorkAges 3–18 - NCT07661095RecruitingPhase 1
Study of CRD3874-SI for relapsed or refractory AML
This trial tests a new drug, CRD3874-SI, for people whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The goal is to see if this drug can help control the leukemia.
New York, New YorkAges 18 years+ - NCT05963971Recruiting
Bilingual online program to prevent weight gain in childhood leukemia
This trial tests a bilingual, online program to help children and teens who have ALL (a type of leukemia) stay at a healthy weight during the maintenance phase of treatment. It may help lower the chance of gaining too much weight while on chemotherapy.
New York, New YorkAges 5–21 - NCT04293562RecruitingPhase 3
Comparing chemotherapy options for newly diagnosed AML in young patients
This trial compares standard chemotherapy with newer drug combinations (CPX-351 and gilteritinib) for children and young adults with acute myeloid leukemia (AML), a type of blood cancer. It aims to find which treatment works better and who might benefit from targeted therapy based on specific genetic changes (FLT3 mutations).
New York, New YorkAges 6 months–21 years - NCT04512716RecruitingEarly Phase 1
Radioimmunotherapy then CD19 CAR T for hard-to-treat blood cancers
This early-phase study tests a two-step treatment: first a targeted radioactive antibody (131-I apamistamab) and then CD19 CAR T-cell therapy. It is for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) or diffuse large B-cell lymphoma (DLBCL) that is not responding or has come back, aiming to shrink cancer using engineered immune cells.
New York, New YorkAges 18 years+ - NCT06317662RecruitingPhase 2
Adding venetoclax and blinatumomab to chemo for infant leukemia
This trial tests adding two newer medicines (venetoclax and blinatumomab) to standard chemotherapy for infants with a specific type of leukemia. The goal is to see if this combination helps more babies stay cancer-free.
New York, New YorkAges Up to 12 months
Hear when a new Acute Leukemia trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Acute Leukemia trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting acute leukemia studies listed above.
- Memorial Sloan Kettering Cancer Center · 17 studies
- Columbia University Irving Medical Center · 6 studies
- Memorial Sloan Kettering Basking Ridge · 5 studies
- Memorial Sloan Kettering Bergen · 5 studies
- Memorial Sloan Kettering Monmouth · 5 studies
- Memorial Sloan Kettering Nassau · 5 studies
- Memorial Sloan Kettering Westchester · 5 studies
- John Theurer Cancer Center at Hackensack University Medical Center · 4 studies
What taking part in a acute leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting acute leukemia studies in New York.
Common questions
- Are there acute leukemia clinical trials near New York?
- Yes. We're currently tracking 107 recruiting acute leukemia studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a acute leukemia study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a acute leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New acute leukemia studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.